Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10933)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22243)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5651)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (643)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1044)
  6. Springer (981)

More Publishers

Results (22266)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications
    Meeting Abstract

    Perets, R.; Sharma, M.; Strickler, J. H.; Golan, T.; Hollebecque, A.; Henner, W.; Vasilopoulos, A.; Thiele, G. M.; Burns, M. C.; Harding, J. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
    Meeting Abstract

    Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein-Barr virus-associated nasopharyngeal carcinoma
    Meeting Abstract

    Colevas, A. D.; Cohen, R. B.; Park, J. C.; Pfister, D. G.; Massarelli, E.; Li, Z.; Xing, B.; Dinavahi, R.; Mehta, A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma
    Meeting Abstract

    Gounder, M. M.; Rosen, E.; Parikh, A. R.; Conley, A. P.; Hong, D. S.; Sheth, S.; Mai, N.; Sgroe, E.; Mitchell, R.; Picard, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Shah, P. D.; Torres, A.; Aaron, M.; Narayan, V.; Knollman, H. M.; Bradbury, A. R.; DeMichele, A.; Robson, M. E.; Tung, N. M.; Domchek, S. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors
    Meeting Abstract

    Park, W.; Zhang, J.; Dayyani, F.; Shan, J.; Liu, R.; Guo, R.; O'Reilly, E. M.; Liu, Z.; Gao, S.; Wu, X.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes
    Meeting Abstract

    Gay, C. M.; Owonikoko, T. K.; Byers, L. A.; Choudhury, N. J.; Ahmed, S.; Cain, Z.; Qian, X. Z.; Brentnall, M.; Heeke, S.; Poi, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of trial eligibility criteria on enrollment to KRAS(G12C) inhibitor trials in patients with non-small cell lung cancer
    Meeting Abstract

    May, M. S.; Wooster, M.; May, B.; Shu, C. A.; Henick, B. S.; Stoopler, M.; Smith-Marrone, S.; Saqi, A.; Mansukhani, M. M.; Riely, G. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial
    Meeting Abstract

    Chaft, J. E.; Swanson, S.; Lee, J. M.; Lin, J.; Tsukada, H.; Li, T.; Ripley, R. T.; Kaifi, J. T.; Baik, C. S.; Bunn, P. A. Jr.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Bouattour, M.; Cheng, A. L.; Dayyani, F.; Khalil, D.; Li, D.; Liao, C. Y.; LoĢpez, C. L.; Rimassa, L.; Deutsch, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save